Anti-inflammatory drug improves survival in COVID-19 patients

Researchers have found that a targeted therapy with tocilizumab reduced mortality by 30 percent for critically ill COVID-19 patients when administered within the first two days of ICU admission.

Haley Bridger • harvard
Oct. 20, 2020 ~8 min

covid-19 inflammation health-medicine brigham-and-womens-hospital miguel-hernan pro-inflammatory-cytokine tocilizumab

/

1